Perspective Therapeutics provides business updates, strategic priorities

Perspective Therapeutics (CATX) announced strategic priorities for the next 12-18 months. Anticipates multiple clinical updates in the next 12-18 months, including further progress from two ongoing clinical programs and initiation of therapeutic dosing of one new asset based on its next generation targeted radiopharmaceutical technology platform; Four additional new assets being evaluated for IND development, to be guided by first-in-human images; Making progress on plans to expand manufacturing capabilities by improving efficiencies of existing facilities and building out recently acquired sites, while evaluating additional capacity expansion opportunities; Preliminary unaudited cash, cash equivalents and short-term investments of $227.8M as of December 31, 2024 expected to be sufficient to fund current planned clinical milestones and operational investments into late 2026